Characterization of the type 1 interferon response during coronavirus infection.
Published: 2005
Language: eng
Number of pages: 143
Description: SARS is a new human infectious disease with significant morbidity and mortality. A novel coronavirus (CoV) has been identified as the agent responsible. Interferon (IFN)-alpha's exhibit a critical role in host resistance to viral infection and in vitro experiments show that IFNs inhibit the SARS-CoV. IFN alfacon-1 is a synthetic IFN-alpha shown to be more potent than other type 1 IFNs. A pilot study was conducted in our laboratory to evaluate the potential clinical benefit and safety of IFN alfacon-1 in SARS treatment. Clinical results suggest that use of IFN alfacon-1 improved disease outcomes. To understand the role of IFN alfacon-1 against the SARS-CoV we studied gene expression profiles in the PBMC of SARS patients. We observe IFN-specific regulated gene expression, possibly associated with reduced viral load, and improved disease outcomes. In parallel, using the mouse CoV, MHV-1, we provide insights into IFN-activated signaling pathways that confer antiviral activity.
Notes: Source: Masters Abstracts International, Volume: 44-02, page: 0814.

Thesis (M.Sc.)--University of Toronto, 2005.

Electronic version licensed for access by U. of T. users.

GERSTEIN MICROTEXT copy on microfiche (2 microfiches).